Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.

被引：0
|
作者：
Zurita, Amado J.
Tidwell, Rebecca Slack
Troncoso, Patricia
Chapin, Brian Francis
Harris, Deborah
Pisters, Louis L.
Araujo, John C.
Pettaway, Curtis Alvin
Aparicio, Ana
Tu, Shi-Ming
Papadopoulos, John N.
Wang, Jennifer
Logothetis, Christopher
Pagliaro, Lance C.
Davis, John W.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5078
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis
    Masahiro Nozawa
    Takeshi Inagaki
    Kazuhiro Nagao
    Tsukasa Nishioka
    Takahiro Komura
    Atsunobu Esa
    Michio Kitagawa
    Masaaki Imanishi
    Yasunari Uekado
    Takatoshi Ogawa
    Hiroshi Kajikawa
    Shigeya Uejima
    Hideyasu Matsuyama
    Isao Hara
    Hirotsugu Uemura
    International Journal of Clinical Oncology, 2014, 19 : 693 - 701
  • [32] A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer
    Palmbos, Phillip L.
    Daignault-Newton, Stephanie
    Tomlins, Scott A.
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia K.
    Kelly, Wm. Kevin
    Arora, Vivek K.
    Antonarakis, Emmanuel S.
    Siddiqui, Javed
    Jacobson, Jon A.
    Davenport, Matthew S.
    Robinson, Dan R.
    Chinnaiyan, Arul M.
    Knudsen, Karen E.
    Hussain, Maha
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3017 - 3027
  • [33] Results of a Phase III Trial of Optimal Sequencing of Dose Escalated Radiation (XRT) and 6 Months Androgen Deprivation Therapy (ADT) in Prostate Cancer
    Malone, S.
    Eapen, L.
    Kendal, W. S.
    MacRae, R. M.
    Perry, G.
    Malone, K.
    Bowen, J.
    Craig, J.
    Grimes, S.
    Morgan, S. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S33 - S33
  • [34] PHASE II RANDOMIZED TRIAL OF OPTIMAL RECURRENCE-DIRECTED THERAPY (RDT) WITHOUT OR WITH ANDROGEN-DEPRIVATION THERAPY (ADT) IN RADIO-RECURRENT OLIGO-METASTATIC HORMONE/CASTRATE SENSITIVE PROSTATE CANCER (ROMCSPC): THE OCOG-RATIONAL-PCS TRIAL
    Gouveia, Andre
    Vavassis, Peter
    Mesci, Aruz
    Hotte, Sebastien
    Berlin, Alejandro
    Zukotynski, Katherine
    Morgan, Scott
    Dayes, Ian
    Perlis, Nathan
    Wright, Jim
    Pond, Gregory
    Niazi, Tamim
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S54 - S55
  • [35] Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).
    Williams, Scott G.
    Davis, Ian D.
    Sweeney, Christopher
    Stockler, Martin R.
    Martin, Andrew James
    Hague, Wendy
    Coskinas, Xanthi
    Yip, Sonia
    Tu, Emily
    Chan, Howard
    Lawrence, Nicola Jane
    McDermott, Ray
    Hughes, Simon
    Marchesin, Vittorio
    Deignan, Olwyn
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).
    Williams, Scott
    Davis, Ian D.
    Sweeney, Christopher
    Stockler, Martin R.
    Martin, Andrew James
    Hague, Wendy
    Coskinas, Xanthi
    Yip, Sonia
    Tu, Emily
    Lawrence, Nicola Jane
    Nayar, Namrata
    McDermott, Ray
    Kelly, Paul
    Deignan, Olwyn
    Hughes, Simon
    Fonteyne, Valerie
    Tombal, Bertrand F.
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] Improving Bone Health in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: Results of a Randomized Phase 2 Trial
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Hamidi, Maryam S.
    Cheung, Angela M.
    Tomlinson, George A.
    Manokumar, Tharsika
    Samadi, Osai
    Sandoval, Joanna
    Durbano, Sara
    Warde, Padraig
    Jones, Jennifer M.
    CANCER, 2018, 124 (06) : 1132 - 1140
  • [38] Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.
    Nabid, Abdenour
    Garant, Marie-Pierre
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Lemaire, Celine
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Carrier, Nathalie
    Duclos, Marie
    Souhami, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Timing of androgen-deprivation therapy and radical radiotherapy in localized prostate cancer: a phase III randomized controlled trial
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (08) : 738 - 739
  • [40] Effect of ß-hydroxy-ß-methylbutyrate (HMB) on muscle strength in older men with prostate cancer (Pca) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial.
    Bylow, Kathryn A.
    Kilari, Deepak
    Riese, Matthew John
    Burfeind, John
    Stolley, Melinda
    Prost, Robert W.
    Musto, Kaylinn
    Neilson, Raquel
    Szabo, Aniko
    Thomas, James P.
    Ng, Alexander V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345